Jefferies Starts Roivant Sciences (ROIV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P stumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Roivant Sciences (ROIV) Stock Surges 20% as Three Street Firms Initiate Coverage With Positive Ratings
October 26, 2021 8:47 AM EDTShares of Roivant Sciences (NASDAQ: ROIV) are up over 20% in pre-open Tuesday after the company received positive ratings at three Street research firms.
Analysts at Jefferies, Truist and Cowen started research coverage of Roivant at Buy or equivalent. Earlier this month, Roivant closed its $7 billion SPAC deal with Montes Archimedes, agreed in May.
Cowen analyst started at Outperform as the ROIV stock price offers a solid entry point. Shares of the company are... More
Truist Securities Starts Roivant Sciences (ROIV) at Buy
October 26, 2021 6:09 AM EDTTruist Securities analyst Robyn Karnauskas initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $15.00.
The analyst commented, "Roivants novel business model underappreciated by investors, in our view; with their evolving AI technology platform and... More
Cowen Starts Roivant Sciences (ROIV) at Outperform
October 26, 2021 5:38 AM EDTCowen analyst Yaron Werber initiates coverage on Roivant Sciences (NASDAQ: ROIV) with an Outperform rating.
The analyst commented, "Roivant aims to revolutionize drug development by integrating multiple subsidiaries discovery platforms with others manufacturing/clinical resources. Dermavants tapinarof is highly promising based on consultant... More
